Genetic Signatures (ASX:GSS) - Hisse Senedi Fiyatı, Haberler ve Analizler

GSS Stoklara Genel Bakış

Genetic Signatures Limited Avustralya, Asya Pasifik, Avrupa, Orta Doğu, Asya ve Amerika'da moleküler tanı şirketi olarak faaliyet göstermektedir. Daha fazla detay

GSS temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	6/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 84% daha düşük bir oranda işlem görüyor

Kazançların yılda 98.62% oranında artması öngörülüyor

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Genetic Signatures Limited Rakipler

Proteomics International Laboratories

ASX:PIQ

AU$89.1m

Trajan Group Holdings

ASX:TRJ

AU$155.3m

EZZ Life Science Holdings

ASX:EZZ

AU$127.5m

Cryosite

ASX:CTE

AU$43.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Genetic Signatures
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.72
52 Haftanın En Yüksek Seviyesi	AU$0.85
52 Haftanın En Düşük Seviyesi	AU$0.38
Beta	0.054
11 Aylık Değişim	12.11%
3 Aylık Değişim	1.06%
1 Yıllık Değişim	44.95%
33 Yıllık Değişim	-42.37%
5 Yıllık Değişim	-34.77%
Halka arzdan bu yana değişim	47.94%

Son Haberler & Güncellemeler

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

Hissedar Getirileri

	GSS	AU Life Sciences	AU Pazar
7D	0.3%	-6.0%	1.5%
1Y	44.9%	11.8%	17.2%

Getiri vs. Endüstri: GSS geçen yıl % 11.8 oranında getiri sağlayan Australian Life Sciences sektörünü aştı.

Getiri vs Piyasa: GSS geçen yıl % 17.2 oranında getiri sağlayan Australian Piyasasını aştı.

Fiyat Oynaklığı

Is GSS's price volatile compared to industry and market?
GSS volatility
GSS Average Weekly Movement	6.6%
Life Sciences Industry Average Movement	11.2%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

İstikrarlı Hisse Senedi Fiyatı: GSS son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: GSS 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2001	n/a	Allison Rossiter	www.geneticsignatures.com

Genetic Signatures Limited Avustralya, Asya Pasifik, Avrupa, Orta Doğu, Asya ve Amerika'da moleküler tanı şirketi olarak faaliyet göstermektedir. Şirket enterik bakteriler, Enteroagregatif E.coli aggR ve aaiC, enterik viral, enterik protozoan, enterik protozoan extended, enterik mikrosporidia, solunum patojeni, SARS-CoV-2, SARS-CoV-2 respiratory plus, koronavirüs, atipik solunum, boğmaca ve PCP, parainfluenza 4, EasyScreen adı altında STI genital patojen, genişlemiş spektrumlu beta-laktamaz ve karbapenemaz üreten organizmalar, viral menenjit, flavivirüs dang alfavirüs, flavivirüs refleks, dang tipleme ve alfavirüs refleks Tespit kitleri. Genetic Signatures Limited 2001 yılında kurulmuştur ve merkezi Newtown, Avustralya'dadır.

Genetic Signatures Limited Temel Bilgiler Özeti

Genetic Signatures'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
GSS temel i̇stati̇sti̇kler
Piyasa değeri	AU$158.81m
Kazançlar(TTM)	-AU$17.86m
Gelir(TTM)	AU$13.77m

11.8x

P/S Oranı

-9.1x

F/K Oranı

GSS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
GSS gelir tablosu (TTM)
Gelir	AU$13.77m
Gelir Maliyeti	AU$7.91m
Brüt Kâr	AU$5.86m
Diğer Giderler	AU$23.72m
Kazançlar	-AU$17.86m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.079
Brüt Marj	42.53%
Net Kâr Marjı	-129.74%
Borç/Özkaynak Oranı	0%

GSS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

GSS Stoklara Genel Bakış

Ödüller

Risk Analizi

Genetic Signatures Limited Rakipler

ASX:PIQ

AU$89.1m

ASX:TRJ

AU$155.3m

ASX:EZZ

AU$127.5m

ASX:CTE

AU$43.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Recent updates

Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

Hissedar Getirileri